BioCentury
ARTICLE | Company News

Clinigen launches European managed access program for Beleodaq from Onxeo

May 12, 2017 8:37 PM UTC

Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for Beleodaq belinostat from Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Under the program, Beleodaq will be available on a named patient basis in the U.K., Germany, France, Spain, Italy, Denmark, Sweden, Norway, Finland, Belgium, the Netherlands, Luxembourg and Austria...

BCIQ Company Profiles

Clinigen Group plc

Onxeo S.A.

BCIQ Target Profiles

Histone deacetylase (HDAC)